Compounds > ofloxacin
Page last updated: 2024-11-01

ofloxacin and Neutropenia

ofloxacin has been researched along with Neutropenia in 65 studies

Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.

Neutropenia: A decrease in the number of NEUTROPHILS found in the blood.

Research Excerpts

ExcerptRelevanceReference
"5 g piperacillin/tazobactam 3 times a day in patients with low-risk febrile neutropenia."9.11Once-daily oral levofloxacin monotherapy versus piperacillin/tazobactam three times a day: a randomized controlled multicenter trial in patients with febrile neutropenia. ( Bethe, U; Breuer, K; Cornely, OA; Diehl, V; Fätkenheuer, G; Karthaus, M; Reichert, D; Salzberger, B; Schwonzen, M; Seifert, H; Ullmann, AJ; Wicke, T, 2004)
"Prophylactic treatment with levofloxacin is an effective and well-tolerated way of preventing febrile episodes and other relevant infection-related outcomes in patients with cancer and profound and protracted neutropenia."9.11Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. ( Allione, B; Amadori, S; Bucaneve, G; Buelli, M; Cantaffa, R; Cilloni, D; D'Antonio, D; Del Favero, A; Deliliers, GL; Dionisi, MS; Fabbiano, F; Foà, R; Lauria, F; Martinelli, G; Martino, P; Menichetti, F; Micozzi, A; Nosari, AM; Specchia, G; Zuffa, E, 2005)
"Outpatient oral antibiotic therapy with oral ofloxacin for patients with low risk neutropenia and fever is safe and similar in efficacy to hospitalization and treatment with broad-spectrum parenteral antibiotics."9.09Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever: a prospective, randomized clinical trial. ( Colomer, R; Cortés-Funes, H; García-Carbonero, R; Gómez, C; Hidalgo, M; Hornedo, J; Lumbreras, C; Perea, S; Ruiz, A; Trigo, JM, 1999)
"Despite the use of levofloxacin prophylaxis during the neutropenic period after autologous peripheral blood stem cell transplantation, viridans group (VG) streptococcal bacteremia developed in 6 (16."7.71Bacteremia due to viridans group Streptococci with diminished susceptibility to Levofloxacin among neutropenic patients receiving levofloxacin prophylaxis. ( Khaliq, Y; Litzow, MR; Patel, R; Piper, KE; Razonable, RR; Rouse, MS, 2002)
"Levofloxacin reduced the bacterial infections and delays the onset of fever in chemotherapy-induced neutropenia especially in short duration (< 7 days)."6.74Levofloxacin prophylaxis to prevent bacterial infection in chemotherapy-induced neutropenia in acute leukemia. ( Khan, MA; Rahman, MM, 2009)
" Because the predicted Cmax value is similar to that of western countries, the frequency of adverse effects is thought to be same as in western countries."6.73Population pharmacokinetics of levofloxacin as prophylaxis for febrile neutropenia. ( Fujimoto, Y; Kanbayashi, Y; Matsumoto, Y; Morimoto, Y; Nomura, K; Taniwaki, M, 2008)
" One hundred forty-eight cases received levofloxacin and 137 received amikacin, both in combination with ceftazidime."5.38Empirical therapy with ceftazidime combined with levofloxacin or once-daily amikacin for febrile neutropenia in patients with neoplasia: a prospective comparative study. ( Bompolaki, I; Bozionelou, V; Falagas, ME; Kalpadaki, C; Karageorgopoulos, DE; Koutsounaki, E; Mitsikostas, P; Samonis, G; Sgouros, J; Taktikou, V, 2012)
"Bacteremia was documented in two patients in the O+R group and six in the control group (p=0."5.30Intensified prophylaxis of febrile neutropenia with ofloxacin plus rifampin during severe short-duration neutropenia in patients with lymphoma. ( Brunet, S; Martino, R; Muñoz, L; Sierra, J; Subirà, M; Sureda, A, 1999)
"An open-label randomised clinical trial was designed to compare the efficacy and tolerance of levofloxacin and ciprofloxacin plus phenethicillin for the prevention of bacterial infections in patients with high-risk neutropenia, and to monitor the emergence of antimicrobial resistance."5.12Levofloxacin vs. ciprofloxacin plus phenethicillin for the prevention of bacterial infections in patients with haematological malignancies. ( Huijgens, PC; Janssen, JJ; Leidekker, ME; Simoons-Smit, AM; Timmers, GJ; Vandenbroucke-Grauls, CM, 2007)
"5 g piperacillin/tazobactam 3 times a day in patients with low-risk febrile neutropenia."5.11Once-daily oral levofloxacin monotherapy versus piperacillin/tazobactam three times a day: a randomized controlled multicenter trial in patients with febrile neutropenia. ( Bethe, U; Breuer, K; Cornely, OA; Diehl, V; Fätkenheuer, G; Karthaus, M; Reichert, D; Salzberger, B; Schwonzen, M; Seifert, H; Ullmann, AJ; Wicke, T, 2004)
"These results suggest that tandem cycles of concurrent 96-h infusions of dexrazoxane and high-dose doxorubicin can be administered with minimal cardiac toxicity, and have activity in patients with recurrent sarcomas."5.11Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malignancies. ( Al-Khadimi, Z; Chow, WA; Doroshow, JH; Frankel, P; Lawrence, J; Leong, L; Lim, D; Longmate, J; Margolin, K; Morgan, RJ; Raschko, J; Shibata, S; Somlo, G; Synold, TW; Tetef, ML; Twardowski, P; Yen, Y, 2004)
"These findings suggest that, despite increasing rates of antimicrobial resistance, levofloxacin prophylaxis during neutropenia may have a beneficial impact on morbidity and infection-related mortality."5.11Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancies. ( Döhner, H; Kern, P; Kern, WV; Marre, R; Reuter, S; Sigge, A; von Baum, H, 2005)
"Prophylactic treatment with levofloxacin is an effective and well-tolerated way of preventing febrile episodes and other relevant infection-related outcomes in patients with cancer and profound and protracted neutropenia."5.11Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. ( Allione, B; Amadori, S; Bucaneve, G; Buelli, M; Cantaffa, R; Cilloni, D; D'Antonio, D; Del Favero, A; Deliliers, GL; Dionisi, MS; Fabbiano, F; Foà, R; Lauria, F; Martinelli, G; Martino, P; Menichetti, F; Micozzi, A; Nosari, AM; Specchia, G; Zuffa, E, 2005)
"Among patients receiving chemotherapy for solid tumors or lymphoma, the prophylactic use of levofloxacin reduces the incidence of fever, probable infection, and hospitalization."5.11Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. ( Billingham, L; Bower, M; Cullen, M; Fernando, I; Gaunt, C; Gollins, S; Hastings, M; Huddart, R; Rea, D; Simmonds, P; Stanley, A; Steven, N; Stuart, N, 2005)
"Outpatient oral antibiotic therapy with oral ofloxacin for patients with low risk neutropenia and fever is safe and similar in efficacy to hospitalization and treatment with broad-spectrum parenteral antibiotics."5.09Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever: a prospective, randomized clinical trial. ( Colomer, R; Cortés-Funes, H; García-Carbonero, R; Gómez, C; Hidalgo, M; Hornedo, J; Lumbreras, C; Perea, S; Ruiz, A; Trigo, JM, 1999)
" After an initial work-up for fever, patients were randomized to receive oral ofloxacin 400 mg immediately and twice daily thereafter in the hospital or as outpatients."5.08Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: results of a prospective randomized trial. ( Aziz, Z; Karim, M; Khan, MA; Khan, WA; Malik, IA, 1995)
" We conducted a prospective non-randomised trial to evaluate the efficacy of administration of oral ofloxacin by caregivers to paediatric cancer patients with fever and neutropenia."5.08Out-patient management of febrile neutropenia in indigent paediatric patients. ( Malik, IA, 1997)
"A multicenter prospective nonrandomized trial was conducted to evaluate the efficacy of self-administered oral ofloxacin in the treatment of cancer patients with fever and neutropenia."5.07Self-administered antibiotic therapy for chemotherapy-induced, low-risk febrile neutropenia in patients with nonhematologic neoplasms. ( Aziz, Z; Karim, M; Khan, WA; Malik, IA, 1994)
" In a prospective, randomized, open trial, we evaluated the efficacy and safety of oral roxithromycin (150 mg twice daily) as additional antibacterial prophylaxis in 131 adult patients with acute leukemia and bone marrow transplant recipients receiving oral ofloxacin."5.07A randomized trial of roxithromycin in patients with acute leukemia and bone marrow transplant recipients receiving fluoroquinolone prophylaxis. ( Arnold, R; Hay, B; Kern, P; Kern, WV; Marre, R, 1994)
"We evaluated the effectiveness of ofloxacin (OFX) administered for prophylactic purposes during 77 episodes of neutropenia (less than 500/mm3) in 54 patients with hematological malignancies and to combat infection in 17 patients with both hematological malignancies and secondary infections."5.07Use of ofloxacin in prevention and treatment of secondary infections in hematological malignancies. ( Okuma, M; Sawada, H; Tashima, M, 1991)
" We explored the effects of neutropenia on the outcome of doxycycline and gentamicin therapy."3.74Comparison of 2 antibiotics that inhibit protein synthesis for the treatment of infection with Yersinia pestis delivered by aerosol in a mouse model of pneumonic plague. ( Bassett, J; Drusano, GL; Heine, HS; Kinzig-Schippers, M; Louie, A; Miller, L; Sorgel, F; Sullivan, LJ, 2007)
"In this controlled before and after observational study, moxifloxacin chemoprophylaxis was used during prolonged neutropenia in haemato-oncological patients (period 2; 282 episodes)."3.73Moxifloxacin prophylaxis in neutropenic patients. ( Bommer, M; Döhner, H; Kern, P; Kern, WV; Marre, R; Reuter, S; Sigge, A; von Baum, H, 2006)
"Vancomycin has been used with increased frequency during the past 15 years and the most common toxicity with this drug is the red man syndrome ."3.71Uncommon vancomycin-induced side effects. ( Baptista, MI; Da Cunha, CA; Kondo, W; Martins, LT; Rocha, JL, 2002)
"We report a case of bacteremia due to Abiotrophia species in a patient with neutropenic fever and cancer who was receiving levofloxacin prophylaxis, followed by empirical therapy with cefepime; the organism was resistant to both antibiotics."3.71Abiotrophia bacteremia in a patient with neutropenic fever and antimicrobial susceptibility testing of Abiotrophia isolates. ( Crawford, S; Jorgensen, JH; McElmeel, ML; Murray, CK; Walter, EA, 2001)
"Despite the use of levofloxacin prophylaxis during the neutropenic period after autologous peripheral blood stem cell transplantation, viridans group (VG) streptococcal bacteremia developed in 6 (16."3.71Bacteremia due to viridans group Streptococci with diminished susceptibility to Levofloxacin among neutropenic patients receiving levofloxacin prophylaxis. ( Khaliq, Y; Litzow, MR; Patel, R; Piper, KE; Razonable, RR; Rouse, MS, 2002)
"Ten patients with newly diagnosed haematological malignancy were given ofloxacin, 400 mg daily orally, for antibacterial prophylaxis during neutropenia."3.68Absorption of oral ofloxacin after cytotoxic chemotherapy for haematological malignancy. ( Blundell, EL; Brown, NM; Chown, SR; MacGowan, AP; Reeves, DS; Slade, RR; White, LO, 1993)
"Levofloxacin reduced the bacterial infections and delays the onset of fever in chemotherapy-induced neutropenia especially in short duration (< 7 days)."2.74Levofloxacin prophylaxis to prevent bacterial infection in chemotherapy-induced neutropenia in acute leukemia. ( Khan, MA; Rahman, MM, 2009)
"Febrile neutropenia is an expected complication during treatment of aggressive hematological malignancies and hematopoietic cell transplantation."2.73The clinical impact of antibacterial prophylaxis and cycling antibiotics for febrile neutropenia in a hematological malignancy and transplantation unit. ( Craig, M; Cumpston, AD; Devetten, MP; Ericson, SG; Hobbs, GR; Sarwari, AR, 2007)
" Because the predicted Cmax value is similar to that of western countries, the frequency of adverse effects is thought to be same as in western countries."2.73Population pharmacokinetics of levofloxacin as prophylaxis for febrile neutropenia. ( Fujimoto, Y; Kanbayashi, Y; Matsumoto, Y; Morimoto, Y; Nomura, K; Taniwaki, M, 2008)
" Pharmacokinetic parameters of levofloxacin, including the maximum serum concentration (C(max)), time to C(max) (T(max)), area under the concentration-time curve (AUC), volume of distribution at steady state (V(ss)/F) and clearance (CL/F) were not statistically different at first dose and during neutropenia."2.71Pharmacokinetics and effects on bowel and throat microflora of oral levofloxacin as antibacterial prophylaxis in neutropenic patients with haematological malignancies. ( Dijstelbloem, Y; Huijgens, PC; Simoons-Smit, AM; Timmers, GJ; Touw, DJ; van Winkelhoff, AJ; Vandenbroucke-Grauls, CM, 2004)
"Both cancer centers differed in prophylactic antibiotic policies."2.69Bacteremia and fungemia in pediatric versus adult cancer patients after chemotherapy: comparison of etiology, risk factors and outcome. ( Foltinova, A; Kaiserova, E; Kiskova, M; Kovacicova, G; Krchnakova, A; Krcmery, V; Krupova, I; Kunova, A; Trupl, J; West, D, 1998)
"Ciprofloxacin was therefore superior to the other two fluoroquinolones in preventing infections due to Gram-negative bacteria in this population of neutropenic patients."2.67Comparison of ciprofloxacin, ofloxacin and pefloxacin for the prevention of the bacterial infection in neutropenic patients with haematological malignancies. ( Accorsi, P; Betti, S; D'Antonio, D; Dell'Isola, M; Favalli, C; Fioritoni, G; Iacone, A; Parruti, G; Piccolomini, R; Quaglietta, AM, 1994)
" three times daily with dosage adjustment according to renal function and body weight (group 2)."2.67Empiric treatment of serious infections in patients with cancer: randomised comparison of two combinations. ( Maiche, AG; Teerenhovi, L, 1991)
"Ofloxacin was superior to co-trimoxazole in preventing infection in this population of neutropenic patients."2.67Ofloxacin versus co-trimoxazole for prevention of infection in neutropenic patients following cytotoxic chemotherapy. ( Chan, TK; Chau, PY; Lam, WK; Liang, RH; So, SY; Todd, D; Yung, RW, 1990)
"Thus, up to date management of cancer patients, in addition to other supportive care modalities, should also incorporate diagnostic methods and therapy of infections."2.47[Treatment and prevention of infections in cancer patients with neutropenia]. ( Sinkó, J, 2011)
"Patients who are treated for acute leukemia should be offered prophylaxis with ciprofloxacin or levofloxacin."2.43Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions. ( Bucaneve, G; Cullen, M; Fraser, A; Gafter-Gvili, A; Kern, WV; Leibovici, L; Paul, M, 2006)
" One hundred forty-eight cases received levofloxacin and 137 received amikacin, both in combination with ceftazidime."1.38Empirical therapy with ceftazidime combined with levofloxacin or once-daily amikacin for febrile neutropenia in patients with neoplasia: a prospective comparative study. ( Bompolaki, I; Bozionelou, V; Falagas, ME; Kalpadaki, C; Karageorgopoulos, DE; Koutsounaki, E; Mitsikostas, P; Samonis, G; Sgouros, J; Taktikou, V, 2012)
"Antofloxacin hydrochloride is a new fluoroquinolone antibiotic with broad-spectrum in vitro activity."1.35Pharmacokinetics/pharmacodynamics of antofloxacin hydrochloride in a neutropenic murine thigh model of Staphylococcus aureus infection. ( Xiao, XM; Xiao, YH, 2008)
" In these strains, levofloxacin ED(50)s were 2- to 10-fold lower than the ED(50)/MIC ratios in the other strains and 90% E(max) AUC/MIC ratios were 2- to 4-fold lower than those predicted from pharmacodynamic modeling of efficacy against other strains."1.33Pharmacodynamics of levofloxacin against Pseudomonas aeruginosa with reduced susceptibility due to different efflux pumps: do elevated MICs always predict reduced in vivo efficacy? ( Cho, D; Corcoran, E; Dudley, MN; Griffith, DC; Lee, A; Lofland, D; Lomovskaya, O, 2006)
"Levofloxacin was somewhat more active against methicillin-resistant Staphylococcus aureus isolates."1.31Comparative in vitro activity of levofloxacin and ciprofloxacin against bacterial isolates from neutropenic patients. ( Catamo, G; D'Antonio, D; D'Ercole, S; Di Bonaventura, G; Piccolomini, R, 2002)
"Bacteremia was documented in two patients in the O+R group and six in the control group (p=0."1.30Intensified prophylaxis of febrile neutropenia with ofloxacin plus rifampin during severe short-duration neutropenia in patients with lymphoma. ( Brunet, S; Martino, R; Muñoz, L; Sierra, J; Subirà, M; Sureda, A, 1999)

Research

Studies (65)

TimeframeStudies, this research(%)All Research%
pre-19901 (1.54)18.7374
1990's23 (35.38)18.2507
2000's37 (56.92)29.6817
2010's4 (6.15)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Xiao, XM1
Xiao, YH1
Gupta, A1
Swaroop, C1
Agarwala, S1
Pandey, RM1
Bakhshi, S1
Petrosillo, N1
Bellesso, M1
Costa, SF1
Pracchia, LF1
Santos Dias, LC1
Chamone, D1
Dorlhiac-Llacer, PE1
Rahman, MM1
Khan, MA2
Sinkó, J1
Samonis, G1
Koutsounaki, E1
Karageorgopoulos, DE1
Mitsikostas, P1
Kalpadaki, C1
Bozionelou, V1
Bompolaki, I1
Sgouros, J1
Taktikou, V1
Falagas, ME1
Schuette, W1
Nagel, S1
von Weikersthal, LF1
Pabst, S1
Schumann, C1
Deuss, B1
Salm, T1
Roscher, K1
Dickgreber, N1
Di Bonaventura, G3
D'Antonio, D5
Catamo, G2
D'Ercole, S1
Piccolomini, R4
Rocha, JL1
Kondo, W1
Baptista, MI1
Da Cunha, CA1
Martins, LT1
Gracia Escudero, A1
Martín González, M1
Giménez Garrido, F1
Clavero Farré, C1
García Pérez, MJ1
Alvarez Corral, G1
Reyes Bertos, A1
Villegas Maldonado, G1
Rodríguez Cuartero, A1
Nakayama, K1
Ishida, Y1
Ohtsuka, M1
Kawato, H1
Yoshida, K2
Yokomizo, Y1
Ohta, T1
Hoshino, K1
Otani, T1
Kurosaka, Y1
Ishida, H1
Lee, VJ1
Renau, TE1
Watkins, WJ1
Timmers, GJ2
Dijstelbloem, Y1
Simoons-Smit, AM2
van Winkelhoff, AJ1
Touw, DJ1
Vandenbroucke-Grauls, CM2
Huijgens, PC2
Cornely, OA1
Wicke, T1
Seifert, H1
Bethe, U1
Schwonzen, M1
Reichert, D1
Ullmann, AJ1
Karthaus, M1
Breuer, K1
Salzberger, B1
Diehl, V1
Fätkenheuer, G1
Prabhu, RM1
Elliott, MA1
Patel, R2
Chow, WA1
Synold, TW1
Tetef, ML1
Longmate, J1
Frankel, P1
Lawrence, J1
Al-Khadimi, Z1
Leong, L1
Lim, D1
Margolin, K1
Morgan, RJ1
Raschko, J1
Shibata, S1
Somlo, G1
Twardowski, P1
Yen, Y1
Doroshow, JH1
Picciani, C1
Spedicato, I1
Reuter, S2
Kern, WV5
Sigge, A2
Döhner, H2
Marre, R4
Kern, P4
von Baum, H2
Bucaneve, G2
Micozzi, A1
Menichetti, F1
Martino, P2
Dionisi, MS1
Martinelli, G1
Allione, B1
Buelli, M1
Nosari, AM1
Cilloni, D1
Zuffa, E1
Cantaffa, R1
Specchia, G1
Amadori, S1
Fabbiano, F1
Deliliers, GL1
Lauria, F1
Foà, R1
Del Favero, A1
Cullen, M3
Steven, N2
Billingham, L2
Gaunt, C1
Hastings, M1
Simmonds, P1
Stuart, N1
Rea, D1
Bower, M1
Fernando, I1
Huddart, R1
Gollins, S1
Stanley, A1
Baden, LR2
Freifeld, AG1
Sepkowitz, KA1
Eller, P1
Pechlaner, C1
Ito, JI1
Tegtmeier, BR1
O'Donnell, MR1
Pasqualotto, AC1
Rosa, DD1
Machado, AL1
Almyroudis, NG1
Segal, BH1
Castagna, L1
Santoro, A1
Griffith, DC1
Corcoran, E1
Lofland, D1
Lee, A1
Cho, D1
Lomovskaya, O1
Dudley, MN1
Bommer, M1
Leibovici, L1
Paul, M1
Gafter-Gvili, A1
Fraser, A1
Leidekker, ME1
Janssen, JJ1
Craig, M1
Cumpston, AD1
Hobbs, GR1
Devetten, MP1
Sarwari, AR1
Ericson, SG1
Louie, A2
Deziel, MR1
Liu, W1
Drusano, GL3
Heine, HS1
Sorgel, F1
Bassett, J1
Miller, L1
Sullivan, LJ1
Kinzig-Schippers, M1
Nomura, K1
Fujimoto, Y1
Morimoto, Y1
Kanbayashi, Y1
Matsumoto, Y1
Taniwaki, M1
Malik, IA4
Khan, WA2
Aziz, Z2
Karim, M3
Baki, M1
Bodrogi, I1
Horti, J1
Géczi, L1
Andriof, E1
Oethinger, M1
Hacker, J1
Iacone, A2
Fioritoni, G2
Parruti, G1
Betti, S2
Quaglietta, AM1
Accorsi, P1
Dell'Isola, M2
Favalli, C1
Hay, B1
Arnold, R1
Brown, NM1
White, LO1
Blundell, EL1
Chown, SR1
Slade, RR1
MacGowan, AP1
Reeves, DS1
Kunova, A2
Trupl, J2
Krcmery, V3
Bow, EJ1
Mandell, LA1
Louie, TJ1
Feld, R1
Palmer, M1
Zee, B1
Pater, J1
Krupova, I1
Kaiserova, E1
Foltinova, A1
Kovacicova, G1
Kiskova, M1
Krchnakova, A1
West, D1
Krupova, Y1
Novotny, J1
Sabo, A1
Mateicka, F1
Hidalgo, M1
Hornedo, J1
Lumbreras, C1
Trigo, JM1
Colomer, R1
Perea, S1
Gómez, C1
Ruiz, A1
García-Carbonero, R1
Cortés-Funes, H1
von Eiff, C1
Peters, G1
Papadimitris, C1
Dimopoulos, MA1
Kostis, E1
Papadimitriou, C1
Anagnostopoulos, A1
Alexopoulos, G1
Papamichael, C1
Gika, D1
Mitsibounas, D1
Stamatelopoulos, S1
Muñoz, L1
Martino, R1
Subirà, M1
Brunet, S1
Sureda, A1
Sierra, J1
Bergogne-Bérézin, E1
Murray, CK1
Walter, EA1
Crawford, S1
McElmeel, ML1
Jorgensen, JH1
Palau, J1
Picón, I1
Angel Climent, M1
Martí, R1
Aznar, E1
Carmen Sanjuán, M1
Máiquez, J1
Ballone, E1
Razonable, RR1
Litzow, MR1
Khaliq, Y1
Piper, KE1
Rouse, MS1
Abbas, Z1
Pizzigallo, E1
Piergallini, A1
Di Gianfilippo, R1
Olioso, P1
Torlontano, G1
Mociková, K1
Svác, J1
Faber, E1
Wildová, B1
Baníková, I1
Maiche, AG1
Teerenhovi, L1
Sawada, H1
Tashima, M1
Okuma, M1
Arning, M1
Wolf, HH1
Aul, C1
Heyll, A1
Scharf, RE1
Scheider, W1
Liang, RH1
Yung, RW1
Chan, TK1
Chau, PY1
Lam, WK1
So, SY1
Todd, D1
Obana, Y1
Nishino, T1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Feasibility Study of the Use of Intermediate Doses of Cytarabine Associated With Autologous Hematopoietic Stem Cells as Consolidation Treatment of Young Adults With Low- or Intermediate-risk de Novo Acute Myeloid Leukemia[NCT03023384]547 participants (Anticipated)Observational [Patient Registry]2016-12-31Recruiting
A Randomized, Prospective Double-Blind, Placebo-Controlled Trial of Prophylactic Oral Levofloxacin Following Chemotherapy for Lymphoma and Solid Tumors[NCT00005590]Phase 30 participants Interventional1999-08-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

3 reviews available for ofloxacin and Neutropenia

ArticleYear
[Treatment and prevention of infections in cancer patients with neutropenia].
    Magyar onkologia, 2011, Volume: 55, Issue:3

    Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antifungal Agents; Antineoplastic Agents; Bacterial In

2011
Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions.
    Cancer, 2006, Oct-15, Volume: 107, Issue:8

    Topics: Acute Disease; Antibiotic Prophylaxis; Antineoplastic Agents; Bone Marrow Transplantation; Ciproflox

2006
[Review of drugs used in the neutropenic period following cytostatic therapy and comparative study of doxycycline and ofloxacin in the treatment of patients with testicular cancer].
    Orvosi hetilap, 1994, Dec-18, Volume: 135, Issue:51

    Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cephalosporins;

1994

Trials

28 trials available for ofloxacin and Neutropenia

ArticleYear
Randomized controlled trial comparing oral amoxicillin-clavulanate and ofloxacin with intravenous ceftriaxone and amikacin as outpatient therapy in pediatric low-risk febrile neutropenia.
    Journal of pediatric hematology/oncology, 2009, Volume: 31, Issue:9

    Topics: Administration, Oral; Adolescent; Ambulatory Care; Amikacin; Amoxicillin-Potassium Clavulanate Combi

2009
Levofloxacin prophylaxis to prevent bacterial infection in chemotherapy-induced neutropenia in acute leukemia.
    Bangladesh Medical Research Council bulletin, 2009, Volume: 35, Issue:3

    Topics: Acute Disease; Adult; Anti-Bacterial Agents; Antibiotic Prophylaxis; Antineoplastic Agents; Bacteria

2009
Randomized phase III trial of docetaxel plus carboplatin with or without levofloxacin prophylaxis in elderly patients with advanced non-small cell lung cancer: the APRONTA trial.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2011, Volume: 6, Issue:12

    Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Antibiotic Prophylaxis; Antineoplastic Combined Chem

2011
[A prospective, controlled, non-randomized study of three cohorts to test the effectiveness of two antibiotics levofloxacin and cotrimoxazol on antibacterial prophylaxis in neutropenic patients].
    Medicina clinica, 2003, Mar-15, Volume: 120, Issue:9

    Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Humans; Leukemia; Levofloxac

2003
Pharmacokinetics and effects on bowel and throat microflora of oral levofloxacin as antibacterial prophylaxis in neutropenic patients with haematological malignancies.
    Bone marrow transplantation, 2004, Volume: 33, Issue:8

    Topics: Administration, Oral; Adult; Aged; Anti-Infective Agents; Digestive System; Drug Resistance, Bacteri

2004
Once-daily oral levofloxacin monotherapy versus piperacillin/tazobactam three times a day: a randomized controlled multicenter trial in patients with febrile neutropenia.
    International journal of hematology, 2004, Volume: 79, Issue:1

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Bacterial Infections; Disease Susceptibili

2004
Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malignancies.
    Cancer chemotherapy and pharmacology, 2004, Volume: 54, Issue:3

    Topics: Adult; Antibiotics, Antineoplastic; Cardiovascular Agents; Doxorubicin; Drug Administration Schedule

2004
Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancies.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2005, Apr-15, Volume: 40, Issue:8

    Topics: Amyloidosis; Anemia, Aplastic; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections;

2005
Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia.
    The New England journal of medicine, 2005, Sep-08, Volume: 353, Issue:10

    Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Antineoplastic Agents; Bacte

2005
Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas.
    The New England journal of medicine, 2005, Sep-08, Volume: 353, Issue:10

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibiotic Prophylaxis; Antineopl

2005
Levofloxacin vs. ciprofloxacin plus phenethicillin for the prevention of bacterial infections in patients with haematological malignancies.
    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2007, Volume: 13, Issue:5

    Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Ciprofloxacin; Cross Infecti

2007
The clinical impact of antibacterial prophylaxis and cycling antibiotics for febrile neutropenia in a hematological malignancy and transplantation unit.
    Bone marrow transplantation, 2007, Volume: 39, Issue:8

    Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacteremia; Drug Administration Schedule; Drug Resist

2007
Population pharmacokinetics of levofloxacin as prophylaxis for febrile neutropenia.
    Internal medicine (Tokyo, Japan), 2008, Volume: 47, Issue:5

    Topics: Adult; Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Dose-Response Relationship, Drug; Female

2008
Self-administered antibiotic therapy for chemotherapy-induced, low-risk febrile neutropenia in patients with nonhematologic neoplasms.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1994, Volume: 19, Issue:3

    Topics: Administration, Oral; Adult; Antineoplastic Agents; Female; Humans; Male; Middle Aged; Neoplasms; Ne

1994
[Review of drugs used in the neutropenic period following cytostatic therapy and comparative study of doxycycline and ofloxacin in the treatment of patients with testicular cancer].
    Orvosi hetilap, 1994, Dec-18, Volume: 135, Issue:51

    Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cephalosporins;

1994
Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: results of a prospective randomized trial.
    The American journal of medicine, 1995, Volume: 98, Issue:3

    Topics: Adult; Aged; Ambulatory Care; Feasibility Studies; Female; Fever; Fever of Unknown Origin; Humans; M

1995
Comparison of ciprofloxacin, ofloxacin and pefloxacin for the prevention of the bacterial infection in neutropenic patients with haematological malignancies.
    The Journal of antimicrobial chemotherapy, 1994, Volume: 33, Issue:4

    Topics: Adult; Aged; Agranulocytosis; Anti-Infective Agents; Bacteremia; Bacterial Infections; Ciprofloxacin

1994
A randomized trial of roxithromycin in patients with acute leukemia and bone marrow transplant recipients receiving fluoroquinolone prophylaxis.
    Antimicrobial agents and chemotherapy, 1994, Volume: 38, Issue:3

    Topics: Acute Disease; Adolescent; Adult; Aged; Anti-Infective Agents; Bone Marrow Transplantation; Cyclospo

1994
Quinolone-based antibacterial chemoprophylaxis in neutropenic patients: effect of augmented gram-positive activity on infectious morbidity. National Cancer Institute of Canada Clinical Trials Group.
    Annals of internal medicine, 1996, Aug-01, Volume: 125, Issue:3

    Topics: Adult; Aged; Anti-Infective Agents; Antineoplastic Agents; Bacteremia; Colony Count, Microbial; Fema

1996
Out-patient management of febrile neutropenia in indigent paediatric patients.
    Annals of the Academy of Medicine, Singapore, 1997, Volume: 26, Issue:6

    Topics: Administration, Oral; Adolescent; Ambulatory Care; Anti-Infective Agents; Child; Child, Preschool; F

1997
Bacteremia and fungemia in pediatric versus adult cancer patients after chemotherapy: comparison of etiology, risk factors and outcome.
    Journal of chemotherapy (Florence, Italy), 1998, Volume: 10, Issue:3

    Topics: Adult; Analysis of Variance; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotic Prophylaxis; A

1998
Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever: a prospective, randomized clinical trial.
    Cancer, 1999, Jan-01, Volume: 85, Issue:1

    Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Amikacin; Anti-Bacterial Agents; Anti-Infective

1999
Outpatient treatment of neutropenic fever with oral antibiotics and granulocyte colony-stimulating factor.
    Oncology, 1999, Volume: 57, Issue:2

    Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Amoxicillin; Anti-Infective Agents; Antineoplast

1999
Randomised comparison of oral ofloxacin alone with combination of parenteral antibiotics in neutropenic febrile patients.
    Lancet (London, England), 1992, May-02, Volume: 339, Issue:8801

    Topics: Administration, Oral; Adult; Amikacin; Anti-Bacterial Agents; Carbenicillin; Cloxacillin; Drug Thera

1992
Empiric treatment of serious infections in patients with cancer: randomised comparison of two combinations.
    Infection, 1991, Volume: 19 Suppl 6

    Topics: Administration, Oral; Cefotaxime; Drug Synergism; Drug Therapy, Combination; Gram-Negative Bacterial

1991
Use of ofloxacin in prevention and treatment of secondary infections in hematological malignancies.
    Chemotherapy, 1991, Volume: 37 Suppl 1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cause of Death; Female; Humans; Leukemia; Lymphoma; Male

1991
Infection prophylaxis in neutropenic patients with acute leukaemia--a randomized, comparative study with ofloxacin, ciprofloxacin and co-trimoxazole/colistin.
    The Journal of antimicrobial chemotherapy, 1990, Volume: 26 Suppl D

    Topics: Bacterial Infections; Ciprofloxacin; Colistin; Humans; Neutropenia; Ofloxacin; Precursor Cell Lympho

1990
Ofloxacin versus co-trimoxazole for prevention of infection in neutropenic patients following cytotoxic chemotherapy.
    Antimicrobial agents and chemotherapy, 1990, Volume: 34, Issue:2

    Topics: Adolescent; Adult; Aged; Agranulocytosis; Antineoplastic Agents; Bacterial Infections; Child; Female

1990

Other Studies

35 other studies available for ofloxacin and Neutropenia

ArticleYear
Pharmacokinetics/pharmacodynamics of antofloxacin hydrochloride in a neutropenic murine thigh model of Staphylococcus aureus infection.
    Acta pharmacologica Sinica, 2008, Volume: 29, Issue:10

    Topics: Animals; Anti-Bacterial Agents; Dose-Response Relationship, Drug; Female; Mice; Mice, Inbred ICR; Mi

2008
[Experience accumulated in hospital setting with levofloxacin, in monotherapy and in association therapy].
    Le infezioni in medicina, 2009, Volume: 17 Suppl 5

    Topics: Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Community-Acquired Infect

2009
Outpatient treatment with intravenous antimicrobial therapy and oral levofloxacin in patients with febrile neutropenia and hematological malignancies.
    Annals of hematology, 2011, Volume: 90, Issue:4

    Topics: Adult; Anti-Bacterial Agents; Cefepime; Cephalosporins; Fever; Hematologic Neoplasms; Home Infusion

2011
Empirical therapy with ceftazidime combined with levofloxacin or once-daily amikacin for febrile neutropenia in patients with neoplasia: a prospective comparative study.
    European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2012, Volume: 31, Issue:7

    Topics: Aged; Amikacin; Anti-Bacterial Agents; Ceftazidime; Drug Therapy, Combination; Female; Fever of Unkn

2012
Comparative in vitro activity of levofloxacin and ciprofloxacin against bacterial isolates from neutropenic patients.
    Chemotherapy, 2002, Volume: 48, Issue:3

    Topics: Anti-Infective Agents; Ciprofloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Neutropenia

2002
Uncommon vancomycin-induced side effects.
    The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases, 2002, Volume: 6, Issue:4

    Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Eosinophilia; Erythema; Female; Fever; Hip Pros

2002
MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 2: achieving activity in vivo through the use of alternative scaffolds.
    Bioorganic & medicinal chemistry letters, 2003, Dec-01, Volume: 13, Issue:23

    Topics: Animals; Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Biological Transport, Active; Car

2003
Apparent failure of moxifloxacin to prevent ciprofloxacin- and levofloxacin-susceptible Pseudomonas aeruginosa bacteremia in neutropenic patients undergoing peripheral blood stem cell transplantation.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2004, Apr-01, Volume: 38, Issue:7

    Topics: Anti-Infective Agents; Aza Compounds; Bacteremia; Ciprofloxacin; Female; Fluoroquinolones; Hematopoi

2004
E-test method for detecting antibiotic synergy against Pseudomonas aeruginosa from neutropenic patients: a cost-effective approach.
    The new microbiologica, 2004, Volume: 27, Issue:3

    Topics: Anemia; Anti-Bacterial Agents; Cefotaxime; Ceftriaxone; Cost-Benefit Analysis; Drug Synergism; Drug

2004
Prophylactic antimicrobial agents and the importance of fitness.
    The New England journal of medicine, 2005, Sep-08, Volume: 353, Issue:10

    Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Antineoplastic Agents; Bacterial Infections; Drug Res

2005
Antibacterial prophylaxis in patients with cancer and neutropenia.
    The New England journal of medicine, 2006, Jan-05, Volume: 354, Issue:1

    Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Humans; Neoplasms; Neutropenia;

2006
Antibacterial prophylaxis in patients with cancer and neutropenia.
    The New England journal of medicine, 2006, Jan-05, Volume: 354, Issue:1

    Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Humans; Neoplasms; Neutropenia;

2006
Antibacterial prophylaxis in patients with cancer and neutropenia.
    The New England journal of medicine, 2006, Jan-05, Volume: 354, Issue:1

    Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Drug Resistance, Bacterial; Hum

2006
Antibacterial prophylaxis in patients with cancer and neutropenia.
    The New England journal of medicine, 2006, Jan-05, Volume: 354, Issue:1

    Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacteria; Bacterial Infections; Drug Resistance, Mult

2006
Antibacterial prophylaxis in patients with cancer and neutropenia.
    The New England journal of medicine, 2006, Jan-05, Volume: 354, Issue:1

    Topics: Adult; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Drug Resistance, Bacteri

2006
Antibacterial prophylaxis in patients with cancer and neutropenia.
    The New England journal of medicine, 2006, Jan-05, Volume: 354, Issue:1

    Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Fever; Hospitalization; Humans;

2006
Pharmacodynamics of levofloxacin against Pseudomonas aeruginosa with reduced susceptibility due to different efflux pumps: do elevated MICs always predict reduced in vivo efficacy?
    Antimicrobial agents and chemotherapy, 2006, Volume: 50, Issue:5

    Topics: Animals; Anti-Bacterial Agents; Area Under Curve; Bacterial Outer Membrane Proteins; Disease Models,

2006
Moxifloxacin prophylaxis in neutropenic patients.
    The Journal of antimicrobial chemotherapy, 2006, Volume: 58, Issue:4

    Topics: Anti-Infective Agents; Antibiotic Prophylaxis; Aza Compounds; Bacteremia; Clostridioides difficile;

2006
Impact of resistance selection and mutant growth fitness on the relative efficacies of streptomycin and levofloxacin for plague therapy.
    Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:8

    Topics: Animals; Anti-Bacterial Agents; Colony Count, Microbial; Disease Models, Animal; Drug Resistance, Ba

2007
Comparison of 2 antibiotics that inhibit protein synthesis for the treatment of infection with Yersinia pestis delivered by aerosol in a mouse model of pneumonic plague.
    The Journal of infectious diseases, 2007, Sep-01, Volume: 196, Issue:5

    Topics: Aerosols; Animals; Anti-Bacterial Agents; Dose-Response Relationship, Drug; Doxycycline; Female; Gen

2007
Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center.
    Antimicrobial agents and chemotherapy, 1994, Volume: 38, Issue:4

    Topics: Anti-Infective Agents; Cancer Care Facilities; Cross Infection; Drug Resistance, Microbial; Drug Uti

1994
Absorption of oral ofloxacin after cytotoxic chemotherapy for haematological malignancy.
    The Journal of antimicrobial chemotherapy, 1993, Volume: 32, Issue:1

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Chromatography, High Pressure Liquid; Humans; Intest

1993
Low incidence of quinolone resistance in gram-negative bacteria after five-years use of ofloxacin in prophylaxis during afebrile neutropenia.
    The Journal of hospital infection, 1996, Volume: 32, Issue:2

    Topics: Anti-Infective Agents; Drug Resistance, Microbial; Gram-Negative Bacteria; Humans; Neutropenia; Oflo

1996
Aetiology, cost of antimicrobial therapy and outcome in neutropenic patients who developed bacteraemia during antimicrobial prophylaxis: a case-control study.
    International journal of antimicrobial agents, 1998, Volume: 10, Issue:4

    Topics: Amikacin; Amphotericin B; Antibiotic Prophylaxis; Bacteremia; Bacterial Infections; Case-Control Stu

1998
In vitro activity of ciprofloxacin, ofloxacin, and levofloxacin against Micrococcus species and Stomatococcus mucilaginosus isolated from healthy subjects and neutropenic patients.
    European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 1998, Volume: 17, Issue:12

    Topics: Anti-Infective Agents; Ciprofloxacin; Gram-Positive Bacterial Infections; Gram-Positive Cocci; Human

1998
Intensified prophylaxis of febrile neutropenia with ofloxacin plus rifampin during severe short-duration neutropenia in patients with lymphoma.
    Leukemia & lymphoma, 1999, Volume: 34, Issue:5-6

    Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Bact

1999
Fluoroquinolone pharmacodynamics: prospective determination of relationships between exposure and outcome.
    Journal of chemotherapy (Florence, Italy), 2000, Volume: 12 Suppl 4

    Topics: Animals; Anti-Infective Agents; Area Under Curve; Dose-Response Relationship, Drug; Drug Administrat

2000
[Resistance and new antibiotic strategies. The other new molecules].
    Presse medicale (Paris, France : 1983), 2000, Dec-02, Volume: 29, Issue:37

    Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Outer Membrane Proteins; Drug Resistance, Mi

2000
Abiotrophia bacteremia in a patient with neutropenic fever and antimicrobial susceptibility testing of Abiotrophia isolates.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2001, May-15, Volume: 32, Issue:10

    Topics: Anti-Bacterial Agents; Bacteremia; Cefepime; Cephalosporins; Drug Resistance, Microbial; Fever; Gram

2001
[Infection in patients with neutropenia that undergo an autologous peripheral blood stem cell transplant due to breast cancer].
    Enfermedades infecciosas y microbiologia clinica, 2001, Volume: 19, Issue:9

    Topics: Acyclovir; Adult; Anti-Infective Agents; Antifungal Agents; Antineoplastic Combined Chemotherapy Pro

2001
Comparison of Etest, agar dilution, broth microdilution and disk diffusion methods for testing in vitro activity of levofloxacin against Staphylococcus spp. isolated from neutropenic cancer patients.
    International journal of antimicrobial agents, 2002, Volume: 19, Issue:2

    Topics: Agar; Anti-Infective Agents; Culture Media; Diffusion; Drug Resistance, Microbial; Humans; Levofloxa

2002
Bacteremia due to viridans group Streptococci with diminished susceptibility to Levofloxacin among neutropenic patients receiving levofloxacin prophylaxis.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2002, Jun-01, Volume: 34, Issue:11

    Topics: Adult; Aged; Anti-Infective Agents; Bacteremia; Chemoprevention; Drug Resistance, Bacterial; Female;

2002
Occurrence of bacteremia in hematologic patients.
    European journal of epidemiology, 1992, Volume: 8, Issue:5

    Topics: Adolescent; Adult; Aged; Bacteremia; Bone Marrow Transplantation; Catheterization; Ciprofloxacin; Fe

1992
[Comparison of Tarivid and Biseptol in the prevention of bacterial infections in patients with acute leukemia].
    Vnitrni lekarstvi, 1992, Volume: 38, Issue:2

    Topics: Bacterial Infections; Female; Humans; Leukemia, Myeloid, Acute; Male; Neutropenia; Ofloxacin; Precur

1992
In vivo activity of ciprofloxacin, ofloxacin, norfloxacin and pipemidic acid against Escherichia coli infections in mice.
    Drugs under experimental and clinical research, 1989, Volume: 15, Issue:2

    Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Escherichia coli Infections; Female; Mice; Microbial

1989